Amunix Pharmaceuticals, Inc. has raised another $117m in venture capital to continue its transition from a company that licenses out its Pro-XTEN technology to one that is developing drugs for its own portfolio. The series B financing follows a $73m series A round that Amunix closed a year ago to fund the company’s development of T-cell engagers and engineered cytokines to treat solid tumors.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?